European Journal of Anaesthesiology:
Abstracts and Programme: EUROANAESTHESIA 2011: The European Anaesthesiology Congress: Evidence-based Practice and Quality Improvement
Galletti, C.; Genovese, A.; De Salvo, G.; Cerrito, L.; Micalizzi, S.; Mazzeo, G.
University Hospital Messina, Department of Anaesthesiology and Intensive Care, Messina, Italy
Background and Goal of Study: To assess that the local infiltration in nosecheek mucosa of mepivacaine 1% plus adrenaline 1:200.000 used alone as analgesic therapy is satisfactory in nose surgery.
This randomized study compares the efficacy of the mepivacaine infiltration vs mepivacaine plus NSAIDs.
Materials and Methods: we examined 90 patients aged from 18 to 51 years, ASA I‐II,divided in two groups: A (30 ptis) underwent to rhinoseptoplasty and B(60 pts)to septoplasty.Afterward groups A and B were randomized in subgroups:A1(15 pts), A2(15 pts), B1(30 pts) and B2(30 pts).
After the induction of general anesthesia all pts were treated with 40 mg of mepivacaine 1% infiltration in nose‐cheek mucosa. Groups A1 and B1 received also the IV administration of 30mg ketorolac before the end of surgery. A VAS scale(0‐10)was administered soon after the awakening and then 1, 3, 6,12 and 18 hours after the end of the surgical procedure.
Results and Discussion: They are reported in the tables below. For the inferential analysis we used the U Mann‐Whitney test.
Only 2 pts in A2 group for VAS > 5 requested rescue pain therapy with ketorolac 30 mg iv. In both subgroups 1 and 2 of groups A and B VAS had p values >0.05.
Conclusion(s): The infiltration of mepivacaine 1% used alone for analgesia after septoplasty and rhinoseptoplasty demonstrates favorable pain relief after surgery, avoids the administration of intravenous NSAIDs and their side effects, and it could represent a savings in health care.